- GlaxoSmithKline Plc GSK has submitted a marketing application to the FDA seeking approval for PRIORIX for use in active immunization against infection by measles, mumps, and rubella (MMR).
- GSK MMR vaccine is available in Europe since 1997. The safety of PRIORIX was evaluated in six clinical studies. Total of 17,393 subjects received at least one dose of either PRIORIX or Measles, Mumps, and Rubella Virus Vaccine, Live (M-M-RII) from Merck & Co Inc MRK.
- The efficacy of PRIORIX was demonstrated based on comparative immunogenicity data with M-M-RII.
- The most commonly reported adverse reactions were pain, redness, swelling, loss of appetite, irritability, drowsiness, and fever.
- If approved, PRIORIX would provide US healthcare providers with another MMR vaccine choice.
- GSK is also seeking approval for PRIORIX administration as a second dose to individuals who received another MMR vaccine.
- Price Action: GSK shares are up 0.3% at $40.25 during the market session on the last check Monday.
- Related content: Benzinga's Full FDA Calendar.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.